Trial Profile
Randomized, Controlled, Blinded, Pilot Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Apr 2022
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Food hypersensitivity
- Focus Therapeutic Use
- Acronyms MAP-X; MAPX; mOIT MAP-X
- 28 Feb 2022 Results evaluating the difference in OIT-related allergic adverse events (AEs) between home versus clinic dose among participants who received omalizumab in randomized phase 2 studies MAPX and MIMIX, presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 28 Feb 2022 Results (n=42) investigating predictors of successful desensitization, presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 30 Mar 2021 Results assessing Immune Changes Beyond Th2 Pathways During Rapid Multifood Immunotherapy enabled with Omalizumab published in the Allergy